ELUT (Elutia) Loans Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELUT Elutia Inc ELUT
34 GF Score
Price $0.91
GF Value $0.90
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Elutia Loans Receivable?

Elutia ELUT -0.33% 34 Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates ELUT with a GF Score™ of 34/100 and a GF Value™ of $0.90 (Fairly Valued). The stock has 5 warning signs investors should review.

Elutia's Loans Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Elutia Loans Receivable Historical Data

* Premium members only.

The historical data trend for Elutia's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elutia Loans Receivable Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Elutia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ELUT
34GF Score
Elutia Inc ELUT
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elutia Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Elutia (ELUT) has a Loans Receivable of $0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Elutia and its competitors.
Is Elutia's Loans Receivable too high?
Elutia's current Loans Receivable is $0.00 Mil. Overall, Elutia has a GF Score™ of 34/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Elutia's Loans Receivable compare to NSYS and MYO?
Elutia's Loans Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Devices & Instruments company?
A good Loans Receivable depends on the Medical Devices & Instruments industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Elutia and its competitors. Elutia's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elutia stock overvalued right now?
Based on GuruFocus' analysis, Elutia (ELUT) is currently considered Fairly Valued. The stock's GF Value™ is $0.90, compared to a current price of $0.91 — trading 1.3% above its estimated fair value. The current Loans Receivable is $0.00 Mil. Elutia's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Elutia (ELUT), the current Loans Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elutia (ELUT) Overvalued in 2026?

Based on GuruFocus' analysis, Elutia stock appears to be overvalued. The current stock price of $0.91 is trading 1.3% above its estimated GF Value™ of $0.90. GuruFocus considers Elutia to be Fairly Valued.

Key valuation signals for ELUT:

  • Loans Receivable: $0.00 Mil
  • GF Value™: $0.90 vs. price of $0.91 (1.3% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the ELUT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elutia Business Description

Address 20 Firstfield Road, Gaithersburg, MD, USA, 20878
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
34GF Score

Get the complete analysis for ELUT

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.91
Price
$0.90
GF Value